Bringing Biomedical Innovation to Global Markets: TMU Launches Strategic Partnership with Japan’s DCI Partners

A breakthrough in the laboratory is only the beginning. Transforming biomedical discoveries into healthcare solutions that reach patients requires clinical validation, entrepreneurial expertise, investment, regulatory planning, and access to international markets.

Taipei Medical University (TMU) is strengthening that pathway through a new strategic partnership with Japan’s DCI Partners Co., Ltd. (DCI Partners), a leading biotechnology venture capital firm under the Daiwa Securities Group. As the first university in Taiwan to establish a university-level partnership with DCI Partners, TMU is creating a platform that bridges academic research and clinical expertise with startups, international investment, and commercialization opportunities in Japan and beyond.

From Discovery to Market

The partnership is designed to strengthen stages across the innovation ecosystem. By combining TMU contributes an integrated environment encompassing biomedical research, affiliated hospitals and clinical resources, intellectual property development, and startup incubation, while DCI Partners brings experience in biotechnology investment, business development, and commercialization.

Together, the two organizations will support promising technologies as they move toward fundraising, regulatory preparation, and market entry in Japan.

Rather than focusing on a single project, both organizations aim to establish a long-term framework spanning entrepreneurship, talent development, technology transfer, investment engagement, and international collaboration—creating new opportunities and stronger support for researchers, clinicians, and startup teams to translate ideas into practical healthcare solutions.

Opening New Pathways between Taiwan and Japan

Japan is one of Asia’s major biomedical markets, with a well-developed healthcare system, strong pharmaceutical and biotechnology industries, and growing demand for innovative medical technologies. Through DCI Partners’ established industry network and investment expertise, TMU innovators will gain new opportunities to connect with potential investors, industry partners, and commercialization resources in Japan. This gives TMU innovations a launchpad into the Japanese market and opens up opportunities across Asia.

For TMU, the partnership reflects a broader vision: building an innovation ecosystem where research, medicine, entrepreneurship, and international partnership work together from early stages of discovery.

By creating stronger pathways from discovery to commercialization, TMU continues to expand its role in global biomedical innovation, bringing Taiwan’s biomedical innovation to greater visibility and opportunities on the global stage.